CorriXR Therapeutics is on the clinical frontier of gene editing as a transformative pre-clinical stage biotechnology company with a ground-breaking in vivo gene editing therapeutic platform technology. CorriXR Therapeutics advances CRISPR/Cas gene editing technology to develop new genetic medicines directed against drug-resistant solid tumors.
Company Details
- Employees
- 5
- Founded
- 2022
- Address
- 550 S College Ave,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://corrixr.com
- Keywords
- Kazia Therapeutics Limited.
- HQ
- Newark, Delaware
Corrixr Therapeutics Questions
Corrixr Therapeutics's website is http://corrixr.com
Corrixr Therapeutics's LinkedIn profile is https://www.linkedin.com/company/corrixrtherapeutics
Corrixr Therapeutics has
5 employees.
View email and phone details for 5
employees at Corrixr Therapeutics.
Corrixr Therapeutics's industry is
Biotechnology Research
Corrixr Therapeutics's top competitors are
Aldevron,
Spyre Therapeutics,
Altamira Therapeutics,
Secretome Therapeutics,
Cortado Ventures,
Kazia Therapeutics Limited,
Jax Xii Holdings,
Caszyme,
Christianacare Gene Editing Institute,
Broken String Biosciences.
Corrixr Therapeutics's categories are Biotechnology Research
Corrixr Therapeutics's founding year is 2022
